Navigation Links
Cohera Medical Receives ISO 13485 Certification: Company Meets International Standards for Design, Development and Manufacturing of Medical Devices
Date:9/22/2009

PITTSBURGH, Sept. 22 /PRNewswire/ -- Cohera Medical, Inc. announced today that it has received certification to the ISO 13485:2003 International Standard for the Design, Development, and Manufacture of Surgical Adhesives. Receipt of the certification allows Cohera Medical to proceed with the CE Mark registration and approval process for TissuGlu(R), the company's novel internal surgical adhesive, upon completion of development for its first indication to optimize healing and prevent fluid accumulation following abdominoplasty procedures.

The British Standards Institution issued the certification following an assessment and audit of the Company's quality management system and associated policies and procedures. The ISO 13485 certification is a required component of the CE Mark process for registration/approval of medical devices in the European Union.

"This certification represents a significant achievement and major milestone for an emerging company such as Cohera," said Patrick Daly, chief executive officer of Cohera Medical. "Successfully completing this process assists us in moving forward into clinical development of TissuGlu in the European Union."

Chad Coberly, vice president of clinical, regulatory and legal affairs said, "ISO certification validates that the design, development, and manufacturing systems Cohera has implemented will ensure the integrity of the devices we supply to the medical community worldwide. This means that Cohera is now well positioned as it progresses towards human clinical trials and ultimately applying for regulatory approvals for TissuGlu."

About ISO Certification

The International Organization for Standardization ("ISO") is a worldwide federation of national standards bodies. ISO 13485:2003 certification is an international standard that specifies a quality management system for the development, production and distribution of medical devices and related services.

About Cohera Medical

Cohera Medical, Inc. is a Pittsburgh, PA based company that is developing a revolutionary line of surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is an adhesive for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation, small bone fixation, and other plastic surgery indications, which will fill similar market needs in plastic, orthopedic and general surgery. For more information, visit www.coheramed.com. TissuGlu and the other Cohera products are currently for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Data Published in Plastic and Reconstructive Surgery Show Cohera Medicals Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
2. Cohera Medical Names Richard L. Wonsettler as Companys First CFO
3. Cohera Medical Secures $16.1 Million in Series B Financing
4. MSU engineering team designs innovative medical device
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
7. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
8. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
9. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
10. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
11. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Park ... financial planning services to families and business owners in the greater Kansas City ... children with developmental disabilities. , The Lakemary Center is a comprehensive educational resource ...
(Date:1/18/2017)... ... 18, 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), ... for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. ... through thought leader interaction in, live video and interactive digital platforms. , In ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse ... for a reset. The U.S. Apple Association agrees and recommends starting each day ... that contribute to heart disease. , The U.S. Apple Association – which represents apple ...
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has ... the Year. , Each year, Pink Elephant recognizes a new product or ... address a specific business problem or opportunity. The award highlights original innovations that were ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... 2017  Kratom leaves, from a South East ... used to prepare tea-like beverages and commercially manufactured ... annually to increase alertness, enhance well-being and occupational ... aches and pains. PinneyAssociates, review of the scientific ... FDA and DEA in determining the most appropriate ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
Breaking Medicine Technology: